SCHEMBL10043830

SCHEMBL10043830

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3nc(C)cs3)ccc1C)c(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
RAB9A P51151 7/20 0.47
POLB P06746 3/20 0.47
NPC1 O15118 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
MAPT P10636 5/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.41
SYK P43405 1/20 0.40
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SHMT2 P34897 1/20 0.38
PLK4 O00444 1/20 0.37
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043828 0.88 RAB9A (0.48) RAB9APOLBNPC1SMN1; SMN2MAPT
SCHEMBL10043831 0.88 NPC1 (0.56) RAB9APOLBNPC1SMN1; SMN2MAPT
SCHEMBL10043958 0.87 SYK (0.43) POLBMAPTSYKALDH1A1ABL1
SCHEMBL10043821 0.86 SYK (0.49) RAB9APOLBNPC1SMN1; SMN2MAPT
SCHEMBL10043829 0.85 SYK (0.41) RAB9ANPC1MAPTSYKABL1
SCHEMBL10043838 0.85 GAA (0.47) RAB9APOLBNPC1SMN1; SMN2MAPT
SCHEMBL10043823 0.84 HTR2C (0.52) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL10043825 0.84 FGFR1 (0.48) RAB9APOLBNPC1SMN1; SMN2MAPT
SCHEMBL10043835 0.84 HTR2A (0.43) RAB9ANPC1SMN1; SMN2MAPTKMT2A
SCHEMBL10043839 0.83 SYK (0.47) RAB9ANPC1MAPTSYKLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SMARCA2 1391/4885SMARCA4 1328/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SMARCA2 1391/4885SMARCA4 1328/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.